SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

2/9/24 9:03:02 AM ET

Medical/Dental Instruments

Health Care

Get the next $GKOS alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 GLAUKOS CORP COMMON STOCK Cusip #377322102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #377322102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,889,438 Item 6: 0 Item 7: 5,893,983 Item 8: 0 Item 9: 5,893,983 Item 11: 12.059% Item 12: HC Cusip #377322102 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 5,893,983 Item 8: 0 Item 9: 5,893,983 Item 11: 12.059% Item 12: IN Item 1(a). Name of Issuer: GLAUKOS CORP Item 1(b). Address of Issuer's Principal Executive Offices: 229 AVENIDA FABRICANTE SAN CLEMENTE, CA 92672 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 377322102 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 5,893,983 (b) Percent of Class: 12.059% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 5,893,983 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of GLAUKOS CORP. No one other person's interest in the COMMON STOCK of GLAUKOS CORP is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of GLAUKOS CORP at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $GKOS alert in real time by email

Recent Analyst Ratings for

$GKOS

Date	Price Target	Rating	Analyst
10/1/2025	$103.00	Buy	Goldman
5/1/2025	$86.00	Overweight → Equal Weight	Wells Fargo
2/19/2025	$140.00 → $200.00	Neutral → Outperform	Mizuho
12/11/2024	$132.00 → $162.00	Neutral → Buy	Citigroup
12/6/2024	$182.00	Buy	UBS
12/2/2024	$120.00	Equal-Weight → Underweight	Morgan Stanley
7/10/2024	$132.00	Buy → Neutral	Citigroup
5/6/2024	$84.00 → $125.00	Hold → Buy	Jefferies

More analyst ratings

SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

2/9/24 9:03:02 AM ET

$GKOS

Medical/Dental Instruments

Health Care

Get the next $GKOS alert in real time by email

Recent Analyst Ratings for

$GKOS

Date	Price Target	Rating	Analyst
10/1/2025	$103.00	Buy	Goldman
5/1/2025	$86.00	Overweight → Equal Weight	Wells Fargo
2/19/2025	$140.00 → $200.00	Neutral → Outperform	Mizuho
12/11/2024	$132.00 → $162.00	Neutral → Buy	Citigroup
12/6/2024	$182.00	Buy	UBS
12/2/2024	$120.00	Equal-Weight → Underweight	Morgan Stanley
7/10/2024	$132.00	Buy → Neutral	Citigroup
5/6/2024	$84.00 → $125.00	Hold → Buy	Jefferies

More analyst ratings

SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$GKOS

SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$GKOS

$GKOS
Press Releases

Glaukos Announces FDA Approval of Epioxa™

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

$GKOS
FDA approvals

FDA Approval for IDOSE TR issued to GLAUKOS CORP

FDA Approval for TRAVOPROST issued to GLAUKOS CORP

$GKOS
SEC Filings

SEC Form 144 filed by Glaukos Corporation

SEC Form S-8 filed by Glaukos Corporation

SEC Form SCHEDULE 13G filed by Glaukos Corporation

$GKOS
Analyst Ratings

Goldman initiated coverage on Glaukos with a new price target

Glaukos downgraded by Wells Fargo with a new price target

Glaukos upgraded by Mizuho with a new price target

$GKOS
Insider Trading

PRESIDENT & COO Gilliam Joseph E covered exercise/tax liability with 1,056 shares, decreasing direct ownership by 0.94% to 111,706 units (SEC Form 4)

CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $43,541 worth of shares (517 units at $84.22) and covered exercise/tax liability with 483 shares, decreasing direct ownership by 1% to 75,907 units (SEC Form 4)

CHAIRMAN & CEO Burns Thomas William covered exercise/tax liability with 4,059 shares, decreasing direct ownership by 3% to 150,705 units (SEC Form 4)

$GKOS
Leadership Updates

OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

$GKOS
Financials

Glaukos Announces FDA Approval of Epioxa™

Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29

Glaukos Announces Second Quarter 2025 Financial Results

$GKOS
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Glaukos Corporation